I highly recommend Dr. Griffiths. Thorough, professional, and reassuring, her cataract surgery exceeded my expectations. Staff is welcoming, and I can’t wait for my second eye procedure.
Victoria Johnson
Photodynamic Therapy for Retinal Conditions
Who May Benefit From PDT
PDT is not appropriate for every patient or every retinal condition. A Retina Specialist carefully evaluates imaging results and symptoms to determine whether PDT is the right approach, alone or combined with other therapies.
Wet AMD occurs when abnormal blood vessels grow beneath the macula, the small central area of the retina responsible for sharp, detailed vision. These vessels leak fluid or blood, which can damage the macula and threaten central vision. PDT was once the primary treatment for wet AMD and remains a useful option today, particularly for patients who do not respond well to anti-VEGF injections alone or who may benefit from combining both therapies.
Central serous chorioretinopathy, known as CSC, happens when fluid accumulates beneath the central retina, causing blurred or distorted central vision. The chronic form, meaning it persists for several months or keeps returning, responds particularly well to PDT. In fact, PDT is widely considered the preferred first-line therapy for chronic CSC, with many patients achieving complete resolution of fluid after a single treatment session.
Wet AMD is more likely to develop with advancing age, a family history of AMD, smoking, high blood pressure, and a diet low in leafy green vegetables. CSC most commonly affects men between the ages of 20 and 50. Exposure to corticosteroid medications, whether taken by mouth, applied to the skin, or inhaled, can trigger or worsen CSC. High levels of emotional stress have also been associated with CSC, possibly because the body produces its own stress-related hormones that behave similarly to corticosteroids.
Recognizing Symptoms That May Lead to PDT
The symptoms that suggest a patient may benefit from PDT depend on the underlying condition. Knowing what to watch for can help patients seek evaluation before significant vision loss occurs.
Patients with wet AMD often notice blurred or distorted central vision, difficulty reading, or a dark spot developing in the center of their visual field. Straight lines may appear wavy or bent. PDT may be considered when vision loss develops gradually, when anti-VEGF injections have not produced adequate results, or when combination therapy could help reduce the number of injections a patient needs.
Chronic CSC typically causes blurry central vision, a dimming or washing out of colors, and subtle distortion of straight lines or shapes. Because CSC can sometimes resolve on its own in the short term, PDT is typically considered when symptoms persist for several months, keep recurring, or when imaging confirms ongoing fluid beneath the retina. A Retina Specialist will evaluate both symptoms and imaging before recommending treatment.
How Retina Specialists Diagnose and Plan PDT
Before recommending PDT, a Retina Specialist uses a series of imaging tests to understand the exact location, size, and nature of the abnormal blood vessels. These tests guide precise treatment planning.
Fluorescein angiography involves injecting a yellow dye into a vein in the arm. As the dye circulates through the retinal blood vessels, a specialized camera captures rapid photographs. These images reveal the location, size, and pattern of abnormal vessels, helping the Retina Specialist determine whether PDT is appropriate and exactly where to apply the laser.
Indocyanine green angiography, known as ICG, uses a different dye that illuminates deeper layers of blood vessels beneath the retina, called the choroid. ICG is especially valuable for diagnosing CSC and for identifying abnormal vessels that may not appear clearly on standard fluorescein imaging. It helps the Retina Specialist map the precise area to be treated.
Optical coherence tomography, or OCT, is a noninvasive scan that creates detailed cross-sectional images of the retina. OCT shows fluid accumulation, swelling, and structural changes within the retinal layers. Retina Specialists use OCT before PDT to assess the extent of involvement, and again after treatment to monitor whether the fluid has resolved and how well the retina is healing.
PDT as a Treatment: What the Evidence Shows
The role of PDT has evolved over time as new treatments have been developed. Today it is used most often for specific situations where it offers clear advantages, either alone or alongside anti-VEGF therapy.
Visudyne (verteporfin) is FDA-approved for treating a specific type of abnormal vessel growth beneath the central retina caused by wet AMD, pathologic myopia, and ocular histoplasmosis. While PDT was once the primary treatment for wet AMD, anti-VEGF injections have since become the standard of care for most patients because they produce better visual outcomes for a broader range of wet AMD types.
PDT for wet AMD is now generally reserved for cases that have not responded adequately to anti-VEGF therapy alone. It may also be used alongside anti-VEGF medications such as aflibercept, ranibizumab, bevacizumab (used off-label for eye conditions), or faricimab. Combining both approaches may help maintain treatment effectiveness while reducing how often injections are needed.
For chronic central serous chorioretinopathy, PDT has become a well-established and preferred treatment. Many Retina Specialists use a modified approach called half-dose PDT, where the amount of Visudyne is reduced to lower the risk of side effects while still effectively closing the source of fluid leakage. Clinical studies have found that a large majority of chronic CSC patients achieve complete resolution of fluid after a single PDT session. Patients who start with worse baseline vision tend to experience the most meaningful improvement in visual clarity.
Anti-VEGF injections work by blocking vascular endothelial growth factor, a protein that drives abnormal blood vessel growth and leakage. These medications require repeated injections on a schedule that varies by drug and patient response. PDT works through a different mechanism, using a photochemical reaction to physically close abnormal vessels rather than blocking a growth signal.
For wet AMD, anti-VEGF injections typically produce better visual outcomes and remain the first-line treatment. For chronic CSC, PDT is often preferred because anti-VEGF injections have shown limited benefit for that particular condition. A Retina Specialist will recommend the approach that best fits the specific diagnosis and circumstances.
The FDA has approved updated photodynamic laser systems for use with Visudyne (verteporfin), providing Retina Specialists with modern equipment options when performing PDT. Research also continues into refining dosing protocols, particularly half-dose and half-fluence approaches for chronic CSC, with the goal of maximizing effectiveness while minimizing potential side effects.
What to Expect Before, During, and After PDT
Knowing what each stage of the process involves helps patients prepare and recover successfully. PDT is performed in an outpatient setting and does not require general anesthesia.
Before scheduling PDT, a Retina Specialist will perform a thorough eye examination and complete imaging. Patients should inform their care team about all medications they are taking, especially any that increase sensitivity to light. Patients should arrange a ride home, since vision may be temporarily blurry after the procedure. It is also important to have dark sunglasses and protective clothing ready before arriving, as light protection begins immediately after treatment.
The entire PDT procedure typically takes about 20 to 30 minutes. A nurse or technician places an intravenous line in the arm and infuses Visudyne (verteporfin) over approximately 10 minutes. The Retina Specialist then waits briefly for the drug to accumulate in the targeted abnormal vessels before applying the low-energy laser to the treatment area for roughly 83 seconds. The laser is painless. Patients are seated at a specialized instrument similar to what is used during a routine eye exam, and no sedation is needed beyond standard numbing eye drops.
After PDT, patients must avoid direct sunlight and bright indoor lighting for five full days. Visudyne remains active in the body during this time, making the skin and eyes highly sensitive to light. Exposure to sunlight or intense artificial light during this period can cause serious skin burns and eye damage. When going outdoors is necessary, patients should wear long sleeves, gloves, a wide-brimmed hat, and wraparound dark sunglasses that block light from all angles. Normal, dim indoor lighting from lamps is generally safe.
A Retina Specialist will schedule follow-up visits after PDT to monitor the response to treatment using OCT and, when needed, repeat angiography. Because the effects of PDT can sometimes be temporary, with abnormal vessels occasionally reopening over time, additional treatment sessions may be necessary. Patients with wet AMD may also continue anti-VEGF injections alongside PDT. Many patients with chronic CSC achieve lasting results after a single session, though some require retreatment. Keeping every scheduled appointment allows the care team to detect any changes early and adjust the plan accordingly.
Managing Recovery and Long-Term Eye Health
PDT requires a short but important recovery period, and ongoing attention to eye health supports the best possible outcomes over time.
PDT is designed to slow or stop vision loss and, in some cases, improve vision. It does not restore vision that has already been permanently lost from long-standing retinal damage. For patients with wet AMD, the primary goal is to preserve as much central vision as possible. For patients with chronic CSC, resolution of the fluid buildup often leads to noticeable improvements in clarity and reduced visual distortion, though some subtle changes may persist depending on how long the condition was active before treatment.
PDT is generally well tolerated, but it does carry some risks. The most significant concern is photosensitivity during the five days following treatment. Skin that is exposed to bright light during this period can develop severe sunburn-like reactions. In rare cases, Visudyne can cause temporary swelling in the eye that leads to a brief decrease in vision. Other less common side effects include mild back pain during the infusion, reactions at the injection site, and temporary visual disturbances. A Retina Specialist will review all risks before scheduling the procedure.
A few practical habits can help protect retinal health over the long term. Using an Amsler grid, a simple printed chart that helps detect changes in central vision, at home between appointments allows patients to notice any new distortion or blurring and report it promptly. Wearing UV-protective sunglasses outdoors, eating a diet rich in leafy green vegetables and omega-3 fatty acids, avoiding smoking, and managing blood pressure all support overall retinal health. These steps complement formal treatment and monitoring rather than replacing them.
When to Seek Urgent Care
Some vision changes are warning signs of a serious retinal problem that requires immediate attention. Knowing when to act quickly can make a meaningful difference in outcomes.
Do not wait for a scheduled appointment if you experience any of the following symptoms. Seek care from a Retina Specialist or go to an emergency room right away if you notice:
- A sudden increase in floaters, meaning dark spots or strands drifting across your field of vision
- Flashes of light in one or both eyes
- A curtain, shadow, or dark area spreading across your vision
- Sudden loss of vision in one eye
These symptoms can indicate a retinal tear or detachment, which is a medical emergency that requires prompt evaluation regardless of whether you are currently undergoing PDT or another retinal treatment.
Even when vision appears stable, regular follow-up with a Retina Specialist is essential for anyone who has received PDT. Conditions such as wet AMD and chronic CSC can become active again without obvious symptoms in the early stages. OCT imaging and clinical examination allow the care team to detect subtle changes before they cause significant vision loss, and to adjust the treatment plan as needed. Patients should report any new or changing visual symptoms between appointments rather than waiting until the next scheduled visit.
Frequently Asked Questions
Patients often have practical questions about PDT that go beyond the basics. Here are answers to some of the most common concerns.
The laser portion of PDT is painless. The intravenous infusion of Visudyne (verteporfin) feels much like a standard blood draw. Some patients experience mild back discomfort during the infusion, which typically passes quickly. No sedation or general anesthesia is required, and most patients are comfortable throughout the procedure.
This depends on your specific condition and how your eye responds. Many patients with chronic CSC achieve complete fluid resolution after a single session. Patients with wet AMD may require additional sessions, often in combination with ongoing anti-VEGF injections. Your Retina Specialist will review your imaging at each follow-up and adjust the plan based on how your retina is responding.
Many patients can return to indoor work the following day, provided the environment does not involve bright overhead lighting or outdoor exposure. The critical restriction is avoiding direct sunlight and intense light for five full days after treatment. If your work requires time outdoors or involves strong lighting, you may need to modify your duties or take time off during that period. Talk through your specific work situation with your Retina Specialist before the procedure so you can plan accordingly.
If accidental sun exposure happens within five days of treatment, move indoors or into shade immediately and contact your care team for guidance. Visudyne remains active in the body during this window, and sun exposure can cause a photosensitivity reaction resulting in severe skin burns on any exposed area. Wearing long sleeves, gloves, a wide-brimmed hat, and wraparound dark sunglasses for the entire five-day period is the best way to prevent this from happening.
Clinical trials demonstrated that anti-VEGF injections produced superior visual outcomes for most patients with wet AMD compared to PDT alone. Anti-VEGF medications not only slow vision loss but can actually improve vision in many patients. PDT remains a valuable option for cases that do not respond well to anti-VEGF therapy on its own, or as part of a combination approach that may reduce the frequency of injections while maintaining effectiveness.
Coverage for PDT varies by insurance plan and diagnosis. Because PDT is an FDA-approved procedure for specific indications, it is often covered when medically necessary, but prior authorization may be required. Our team can help verify your benefits and discuss available payment options before your treatment is scheduled.
Schedule a Consultation at NewView Eye Center
Our team is committed to providing thorough, personalized care for patients with conditions affecting the retina and overall eye health. If you have been told you may be a candidate for photodynamic therapy, or if you are experiencing changes in your central vision, we encourage you to schedule a consultation with us. We are proud to serve patients across Northern Virginia with the clinical expertise and attention to detail that every patient deserves.
What our Patients Says
Explore More
Find more information about our doctors, services, and technology that keep your eyes healthy and your vision at its best.
Uveitis: Understanding Eye Inflammation and Protecting Your Vision
Retinal Disease: What Every Patient Needs to Know
Laser Floater Removal: Relief for Bothersome Eye Floaters
Vitreous Hemorrhage: Causes, Treatment, and Recovery
Vitrectomy Surgery: What Patients Need to Know
Retinopathy of Prematurity: A Guide for Parents